HAVCR2 and acute myeloid leukemia: In addition, in a phase 1/2 study, sabatolimab, a humanized monoclonal antibody (hIgG4, S228P) directed against the human T-cell immunoglobulin domain and mucin domain-3 (TIM-3) aimed to enhance T-cell killing and inflammatory cytokine production by dendritic cells [23], will be combined with azacytidine to treat MRD-positive AML patients post-HSCT (NCT04623216).